What is Mesoblasts relationship with Angioblast?
Mesoblast is a significant equity holder in Angioblast, and after shareholder approval in November 2006, is currently increasing its equity stake from 33% to 39.2%. Angioblast and Mesoblast are jointly funding and progressing the shared platform technology in preclinical and clinical trials, patent management, technology development and commercialisation. Angioblast was assigned all intellectual property for MPC-related discoveries from the Institute of Medical and Veterinary Science and the Hanson Institute in South Australia , covering composition of matter and enablement of MPCs and Mesoblast has a worldwide exclusive licence for the use of MPCs in all orthopaedic applications.
